Staying The Course: PhRMA Announces ‘Pro-Consumer’ Reform Priorities
This article was originally published in The Pink Sheet Daily
Executive Summary
Recently installed CEO Stephen Ubl presents policy solutions as industry’s best response to ongoing public criticism over high drug prices.
You may also be interested in...
PhRMA CEO: Ubl Pick Brings User Fee, Reimbursement Expertise
Steve Ubl has led AdvaMed for 10 years, raising profile of device industry on Capitol Hill and executing well-regarded public relations campaign of the kind the drug industry might need as it enters political maelstrom on pricing.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.